)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Poltreg
Poltreg (PTG) investor relations material
Poltreg Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary9 Sep, 2026
Executive summary
Continued focus on advanced clinical-stage Treg cell therapies for autoimmune diseases, with ongoing R&D and no significant revenue generation beyond hospital exemption sales.
Maintained strong cash position, supported by public grants and a successful share issue in March 2026.
Strategic milestones include new R&D project funding and a regulatory partnership for EU drug registration.
Financial highlights
Revenue from product sales remained flat at 240k PLN for H1 2026, unchanged year-over-year.
Net loss for H1 2026 was 12,429k PLN, an improvement from 13,968k PLN in H1 2025.
Operating loss narrowed to 12,094k PLN from 14,162k PLN year-over-year.
Cash and equivalents at period end were 22,637k PLN, up from 17,785k PLN at 2025 year-end.
Total assets at 30 June 2026 were 75,142k PLN, down from 87,313k PLN a year earlier.
Outlook and guidance
Management forecasts the need for additional funding to support full R&D plans, with a planned share issue as the primary source.
Flexibility in project spending and cost control measures are in place to extend liquidity if needed.
No material uncertainty identified regarding going concern for the forecast period.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Poltreg
- Pioneering Treg therapies show long-term efficacy and target a vast autoimmune disease market.PTG
Investor presentation - Global TREG therapy leader with proven technology, strong pipeline, and US expansion strategy.PTGInvestor presentation
- Net loss widened to 6.8 million PLN as R&D accelerated, with major clinical and financing milestones achieved.PTGQ1 2026
- Net loss widened to 25.99m PLN as R&D and operating costs rose; major U.S. and EU regulatory progress.PTGQ4 2025
- Net loss nearly doubled as revenue fell, but key clinical and grant milestones were achieved.PTGQ2 2024
- Revenue dropped sharply as clinical and regulatory progress accelerated, with losses offset by strong cash and grants.PTGQ4 2024
- Losses increased as revenue fell, but clinical and patent milestones position the pipeline for future growth.PTGQ3 2024
- Net loss widened on higher R&D costs, but clinical and regulatory milestones advanced.PTGQ3 2025
- Q1 2025 marked higher losses, no sales, and key advances in TREG therapy R&D and partnerships.PTGQ1 2025
Next Poltreg earnings date
Q3 202618 Nov, 2026
Poltreg
Next Poltreg earnings date
Q3 202618 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)